Jonathan W. Goldman, MD

Articles by Jonathan W. Goldman, MD

Osimertinib Proves Frontline Status in EGFR+ Advanced NSCLC

July 21st 2023

Jonathan W. Goldman, MD, discusses the use of osimertinib in the first line setting for patients with non–small cell lung cancer.

Strategies for Managing Adverse Events of Osimertinib for EGFR+ NSCLC

ByJonathan W. Goldman, MD

May 17th 2023

Jonathan W. Goldman, MD, discusses management of the most common adverse events associated with osimertinib in patients with non–small cell lung cancer.

Jonathan W. Goldman, MD

Articles by Jonathan W. Goldman, MD

Osimertinib Proves Frontline Status in EGFR+ Advanced NSCLC

Strategies for Managing Adverse Events of Osimertinib for EGFR+ NSCLC

Latest Updated Articles

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL

Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC

Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma

Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma

LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors